Explore more Johnson & Johnson sites:
Share
Download Report
Back to top
Janssen Pharmaceutical Companies of Johnson & Johnson Selected Novel Therapies - Recent Approvals/Potential Filings* (2021-2025 Key Filings, As Outlined at 2021 Pharm Business Review)
Selective Highlights as of January 24, 2023
Novel Therapies APPROVED
Oncology
RYBREVANT (amivantamab)
Non Small Cell Lung Cancer
CARVYKTI (Ciltacabtagene autoleucel)
Relapsed refractory Multiple Myeloma
teclistamab (BCMA/CD3)
Relapsed Refractory Multiple myeloma
Novel Therapies in REGISTRATION
Oncology
niraparib
Metastatic castration-resistant prostate cancer (mCRPC)
EU
talquetamab (GPRC5D/CD3)
Multiple myeloma
Cardiovascular and Metabolism
aprocitentan
Difficult to treat hypertension
US
Novel Therapies PLANNED FILINGS
Cardiovascular and Metabolism
RPGR AAV Gene Therapy
X-linked retinitis pigmentosa
aprocitentan
Difficult to treat hypertension
EU
Infectious Diseases and Vaccines
RSV Adult Vaccine
RSV vaccine
JNJ-3989 siRNA
HBV/HDV Co-infection
Immunology
Oral IL-23i
Psoriasis
Neuroscience
seltorexant
Adjunctive treatment for major depressive disorder with insomnia symptoms
Aticaprant
Adjunctive treatment for major depressive disorder
nipocalimab
Generalized Myasthenia Gravis
Oncology
TAR-200 (RIS/gemcitabine)
Bladder Cancer
niraparib
Metastatic castration-resistant prostate cancer (mCRPC)
US
Pulmonary Hypertension
Macitentan 75mg
Chronic thromboembolic pulmonary hypertension
Filings/approvals assumed to be in the US and EU unless otherwise noted. This information is accurate as of the date hereof to the best of the Company’s knowledge. Johnson & Johnson assumes no obligation to update this information.
BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; Niraparib licensed from Tesaro; BCMA CAR-T licensed from Legend Biotech; Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S; DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab , Talquetamab); Lazertinib licensed from Yuhan Corporation; Retinal assets (Achromatopsia: AAV-CNGA3, AAV-CNGB3) and (X-Linked Retinitis Pigmentosa: AAV-RPGR) licensed from MeiraGTx;